Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Drug

Betta Pharmaceuticals Secures NMPA Approval for Befotertinib in NSCLC Treatment

Fineline Cube Oct 13, 2023

China-based Betta Pharmaceuticals Co., Ltd. (SHE: 300558) has officially announced its receipt of market approval...

Company Drug

KPC Pharmaceuticals Secures WHO Prequalification for Dihydroartemisinin/Piperaquine

Fineline Cube Oct 13, 2023

Yunnan-based KPC Pharmaceuticals Inc. (SHA: 600422) has announced that its dihydroartemisinin/piperaquine 40mg/320mg formulation has received...

Company

Novartis Halts Phase II Clinical Study for MIJ821 in Major Depressive Disorder

Fineline Cube Oct 12, 2023

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has decided to hold the Phase II clinical...

Company Drug

MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Oct 12, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...

Company

Bayer AG Plans Continued Investment in China Amidst Global Challenges

Fineline Cube Oct 12, 2023

Germany-based multinational corporation Bayer AG (ETR: BAYN) is determined to continue investing in China, as...

Company Drug

Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients

Fineline Cube Oct 12, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...

Company Deals

BMS Expands CAR-T Collaboration with Cellares on Automation Tech

Fineline Cube Oct 12, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares,...

Company Drug

Henlius Pharmaceutical Secures GMP Compliance for PD-1 Inhibitor Serplulimab in Indonesia

Fineline Cube Oct 12, 2023

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced that its partner, PT Kalbe Genexine...

Company Deals

Medilink Therapeutics Enters Global Licensing Agreement with BioNTech for HER3-Targeted Antibody Drug Conjugates

Fineline Cube Oct 12, 2023

Suzhou-based Medilink Therapeutics has announced a strategic cooperation and global licensing agreement with Germany-headquartered BioNTech...

Company Medical Device

Jiangsu BioPerfectus Secures NMPA Approval for Norovirus Nucleic Acid Detection Kit

Fineline Cube Oct 12, 2023

China-based Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading manufacturer of in vitro diagnostic...

Company

Kintor Pharmaceutical Secures NMPA Approval for Phase II Study of GT1708F in Idiopathic Pulmonary Fibrosis

Fineline Cube Oct 12, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced that it has received approval from the...

Company Drug

Yiling Pharmaceutical Secures NMPA Approval for Phase I Study of G201-Na in Premenopausal Women

Fineline Cube Oct 12, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received approval from...

Company

Gritgen Therapeutics Commences Operations of Commercial GMP Facilities in Suzhou

Fineline Cube Oct 12, 2023

Suzhou-based gene therapy specialist, Gritgen Therapeutics Co., Ltd, has announced the validation completion and initiation...

Company Drug

GenFleet Therapeutics’ CDK9 Inhibitor SLS009 Earns Orphan Drug Status for AML

Fineline Cube Oct 12, 2023

Shanghai-based biotechnology company GenFleet Therapeutics has announced that its CDK9 inhibitor, SLS009 (GFH009), has received...

Company Medical Device

Cochlear’s Artificial Cochlear Sound Processor Gains NMPA Approval for Marketing in China

Fineline Cube Oct 11, 2023

Australia-based Cochlear has received marketing approval from the National Medical Products Administration (NMPA) for its...

Company Deals

Jiangsu Recbio Forms Strategic Cooperation for Vaccine Production in Zimbabwe

Fineline Cube Oct 11, 2023

China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced a tripartite strategic cooperation agreement...

Company Drug

Roche’s Forimtamig Receives Tacit Approval for Multiple Myeloma Clinical Trials

Fineline Cube Oct 11, 2023

The Center for Drug Evaluation (CDE) has indicated that Swiss pharmaceutical giant Roche (SWX: ROG)...

Company Deals

Sanofi Partners with BioMap to Accelerate AI-Driven Drug Discovery

Fineline Cube Oct 11, 2023

France-based pharmaceutical giant Sanofi (EPA: SAN) has entered into a strategic partnership with US biotech...

Company Deals

Sino Biopharmaceutical Sells 84.2% Stake in Shanghai CP General Pharmaceutical

Fineline Cube Oct 11, 2023

China-based biotech company Sino Biopharmaceutical Ltd (HKG: 1177) has announced the sale of an 84.2%...

Company Deals

Jiangsu QYuns Therapeutics Plans IPO on Hong Kong Stock Exchange

Fineline Cube Oct 11, 2023

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an...

Posts pagination

1 … 507 508 509 … 711

Recent updates

  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.